Invest in intelligence that delivers



Pfizer’s Velsipity poised to outpace BMS’ Zeposia in ulcerative colitis market, but must head off further competition: analysts


As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model


US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of…


Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for…

Talk to an expert

Gianna Melendez
Franchise Head, Dermatology

Jim Hickey
Franchise Head, Gastroenterology

Maxine Yarnall
Franchise Head, Rheumatology

Meghan Weiss
Franchise Head, Nephrology

Blaine Cloud, PhD
Franchise Head, Neurology

Blaine Cloud, PhD
Franchise Head, Ophthalmology

Sign up for alerts, market insights and exclusive content in your inbox.

Spherix is excited to announce our expansion into an additional, rapidly evolving specialty market:


Throughout 2024, we will be publishing over
10 groundbreaking studies covering a wide range of indications within classical hematology.